NBTX

NANOBIOTIX SA - ADR

About NBTX

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Buy US stocks in Australia starting with NBTX. Open an account and start investing today!

Market Capitalisation

$139.15M

Price-earnings ratio

Dividend yield

0.00%

Volume

686

High today

$4.49

Low today

$4.49

Open price

$4.49

52-week high

$9.13

52-week low

$2.32

NBTX FAQs

How much is one share of NANOBIOTIX SA - ADR?

One share of NANOBIOTIX SA - ADR is valued at $3.94.

What is the ticker symbol for NANOBIOTIX SA - ADR?

The ticker symbol for NANOBIOTIX SA - ADR is NBTX.

How do I buy NBTX shares in Australia?

To buy NBTX stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in NBTX

What is the market capitalisation of NANOBIOTIX SA - ADR NBTX?

As of 30/01/2023 NANOBIOTIX SA - ADR has a market cap of $139M.

What is the 52-week high for NANOBIOTIX SA - ADR stock?

The NANOBIOTIX SA - ADR 52-week high stock price is $9.13.

What is the 52-week low for NANOBIOTIX SA - ADR stock?

The NANOBIOTIX SA - ADR 52-week low stock price is $2.32.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.